Latest Breaking News On - Telmar network technology - Page 1 : comparemela.com

Highlander Post Views: 1,658 UCR’s School of Medicine is partnering with Emalex Biosciences in producing a biological treatment for stuttering and will lead the second phase of clinical trials. UCR will serve as the lead site for a Phase 2 clinical trial that will evaluate the effectiveness of ecopipam, an investigational drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients. Emalex Biosciences who developed ecopipam, will conduct the clinical trial. Ecopipam currently treats talk and speech therapy. However, if the trials continue to show success and are later submitted to the U.S. Food and Drug Administration (FDA), ecopipam could become the leading biological medication to treat stuttering with FDA approval. Furthermore, ecopipam has the possibility of also treating children with Tourette syndrome, a type of disorder which involves “involuntary, repetitive movements and vocalization.”

United statesGerald maguireGranville kirkupEmalex biosciencesUniversity of californiaTelmar network technologySchool of medicineDrug administrationPost viewsNational stutteringஒன்றுபட்டது மாநிலங்களில்ஜெரால்ட் மக்வைர்பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியாடெல்மார் வலைப்பின்னல் தொழில்நுட்பம்பள்ளி ஆஃப் மருந்துபோஸ்ட் காட்சிகள்